Ovarian Repositioning

New Medicare Benefits Schedule (MBS) Items 35730: Ovarian Repositioning

Page last updated: 21 June 2017

Ovarian Repositioning Fact Sheet (PDF 171 KB)
Ovarian Repositioning Fact Sheet (Word 506 KB)

What does the new procedure involve?

MBS item 35730 covers ovarian repositioning for one or both ovaries to preserve ovarian function, prior to gonadotoxic radiotherapy.

The original MBS item for ovarian transposition (35729) could only be used in conjunction with radical hysterectomy. Patients who required abdominal/pelvic radiotherapy and were at risk of infertility as a result of complications of treatment, could not access existing item 35729. MBS item 35729 will remain on the schedule, unchanged.

What are the patient eligibility requirements?

MBS item 35730 is for women who will be undergoing gonadotoxic radiotherapy, where the patient’s treating specialist determines that the treatment volume and dose of radiation means there is a high probability of the treatment causing infertility.

Fee: $217.80; MBS benefit: 75% = $163.35

This item can be claimed with items from Group T10 Relative Value Guide for Anaesthesia.

Where can the procedure take place?

The procedure can be performed only in hospital.

Relevant organisations

    Australian College of Rural and Remote Medicine

    Australian Medical Association

    Fertility Society of Australia

    The Royal Australasian College of Surgeons

    The Royal Australian and New Zealand College of Obstetricians and Gynaecologists

Find out more

For details of the 1 May 2017 MBS changes, please refer to Health Insurance Legislation Amendment (2017 Measures No. 1) Regulations 2017 (click on the ‘Explanatory Statement’ tab) or visit MBS Online. See the Medical Services Advisory Committee’s website for more information about the committee’s recommendation to list the service.